Details for Patent: 7,439,241

« Back to Dashboard

Which drugs does patent 7,439,241 protect, and when does it expire?

Patent 7,439,241 protects MIRVASO and is included in one NDA.

This patent has seventy-seven patent family members in twenty-four countries.

Summary for Patent: 7,439,241

Title:	Compounds, formulations, and methods for treating or preventing rosacea
Abstract:	In methods, compounds, and topical formulations for treatment of rosacea incorporating compounds represented by the formulas below: ##STR00001## wherein each of R.sub.1, R.sub.2, and R.sub.3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R.sub.4 and R.sub.5 is independently hydrogen, alkyl, or alkoxy; and each of R.sub.6 and R.sub.7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A.sub.1, A.sub.3, and A.sub.4 is independently hydrogen or alkyl; and A.sub.2 is independently hydrogen or hydroxy; and wherein each of B.sub.1, B.sub.2, and B.sub.3 is independently hydrogen, hydroxy, or alkoxy; and each of B.sub.4 and B.sub.5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat rosacea and its symptoms.
Inventor(s):	DeJovin; Jack A. (New Brunswick, NJ), DeJovin; Isabelle Jean (New Brunswick, NJ)
Assignee:	Galderma Laboratories, Inc. (Fort Worth, TX)
Application Number:	10/853,585
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,439,241
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 7,439,241
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 7,439,241

Glossary

Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013		RX	Yes	Yes	➤ Sign Up	➤ Sign Up				TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 7,439,241

Subscribe to access the full database, or try a Free Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	530185	➤ Sign Up
Australia	2004242967	➤ Sign Up
Australia	2005247467	➤ Sign Up
Australia	2011231543	➤ Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.